Management of CAR T-cell Toxicities: Concordance and Divergence Between Healthcare Providers and Expert Consensus Recommendations

Results of recent CCO analysis suggest many healthcare providers are not optimally managing adverse events associated with CAR T-cell therapy administration.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings